Moreover, pooled plasma from the most responsive group demonstrated the ability to inhibit key cancer signaling pathways, such as NF-kB-p65 and focal adhesion kinase, in both cancerous and endothelial cells. The gene discussed is NFKB1; the disease is cancer.